Endometriosis and Assisted Reproductive Technologies: Maximizing Outcomes

Eric S. Surrey, MD¹

¹ Colorado Center for Reproductive Medicine, Lone Tree, Colorado

Semin Reprod Med 2013;31:154–163

Address for correspondence and reprint requests Eric S. Surrey, MD, 10290 Ridgegate Circle, Lone Tree, CO 80124 (e-mail: esurrey@colocrm.com).

Abstract

In vitro fertilization (IVF) represents the most efficient means of overcoming endometriosis-related infertility. Compromised pelvic anatomy and a hostile peritoneal environment are bypassed. Despite the results of early trials, more contemporary outcomes data would suggest that when controlled for age, IVF cycle outcome is not compromised by the presence of endometriosis. One exception to this concept is the finding that patients with ovarian endometriomas demonstrate poorer response to gonadotropin therapy, although it is not clear that this affects the likelihood of implantation. Surgical ablation of superficial endometriosis has no clear impact on IVF pregnancy rates, although a small number of recent trials suggest that pre-cycle resection of deeply infiltrative disease may be beneficial. With the exception of traditional gynecologic indications, there is no evidence to suggest that resection of ovarian endometriomas has any positive impact on cycle outcome. There are, in fact, data demonstrating that resection may exert a deleterious effect on ovarian reserve. A subset of patients will benefit from administration of a prolonged course of a gonadotropin-releasing hormone agonist prior to an IVF cycle. However, the characteristics of that subset have not been identified. It would be logical to consider this approach in women with more advanced disease, severe symptoms, and a history of implantation failure. Data on the impact of other pre-cycle medical interventions such as aromatase inhibitors, danazol, or oral contraceptives are more limited. There is also no evidence to suggest that the ovarian stimulation associated with IVF induces progression of endometriosis.

Keywords
► endometriosis
► in vitro fertilization
► GnRH agonist
► endometrioma
► integrin

The relationships between endometriosis and infertility and possible etiologies have been previously discussed. Although surgical management can overcome anatomical distortion caused by this disease, it would be unlikely that such intervention would have an appreciable effect on the alterations in cytokine concentrations, gene expression, or other inflammatory processes that might impede conception in patients with endometriosis. However, in vitro fertilization (IVF)-embryo transfer should not only bypass abnormal pelvic anatomy but also remove gametes from an otherwise hostile peritoneal environment. The 2010 Society for Assisted Reproductive Technology (SART) Clinic Summary reported that 3777 fresh IVF cycles with a primary indication of endometriosis using nondonor oocytes were initiated in the United States during that year.¹ This represented only 3.9% of the 95,625 total cycles. Given the relatively common occurrence of endometriosis in infertile women, this rather low percentage may reflect the lack of performance of routine diagnostic laparoscopy, the inclusion of minimal endometriosis under the category of “unexplained infertility,” or the inclusion of endometriosis patients under other primary diagnoses, which were believed to be of greater significance, any one of which would result in an underrepresentation of this diagnosis.

In this review, I address the impact, if any, of endometriosis on IVF outcome and whether this impact can be altered by surgical or medical interventions. Lastly, the question of whether ovarian stimulation associated with IVF can have an impact on disease progression is discussed.
Does Endometriosis Affect IVF Outcome?

A controversial issue is whether endometriosis per se exerts a deleterious effect on IVF outcomes. If the primary effect of endometriosis on infertility is a fundamental effect on oocyte quality or implantation, then IVF would not be expected to have a benefit. Several early studies implied that fertilization, implantation, and pregnancy rates in endometriosis patients were significantly compromised in comparison with controls. It is important to note that in these trials, outcomes were compromised in control groups as well. In contrast, Olivennes and colleagues reported a 30% delivery rate per embryo transfer in 360 IVF cycles performed on 214 endometriosis patients in contrast to a 37.5% rate in 166 cycles performed on 111 controls with tubal disease, a difference that was not statistically significant. Others have confirmed these findings.

Barnhart and coworkers performed a meta-analysis addressing this issue and included 27 trials published from 1983 to 1998. The authors concluded that the chance of conceiving from IVF was significantly lower for endometriosis patients than for tubal factor controls (odds ratio [OR]: 0.56; 95% confidence interval [CI]: 0.44 to 0.70). They also reported that endometriosis patients experienced significantly lower fertilization and implantation rates with a lower number of oocytes obtained. Once again, mean implantation and pregnancy rates were low in both groups (12.72% versus 18.08%). Note that these outcome statistics do not generally reflect current practice.

A more recent large retrospective analysis concluded that live-birth rates were similar for patients with endometriosis and tubal factor infertility (66.0% versus 66.7%). Both groups had poorer outcomes than those with unexplained infertility (78.8%). Nevertheless, implantation rates, a more accurate reflection of IVF outcome, were similar among all three groups. According to the 2010 SART registry, age-matched patients with endometriosis fared no differently than the overall population of women undergoing IVF (Table 1).

Does Endometriosis Severity Affect IVF Outcome?

If the overall population of endometriosis patients fare as well as controls in more recent analyses of IVF outcomes, then does this hold true with regard to varying degrees of disease severity? It has been suggested that advanced stage endometriosis may induce dysfunctional granulosa cell estrogen and progesterone receptor expression. Earlier trials had reported significantly lower pregnancy rates after IVF in patients with more advanced disease. However, it is important to note that in these studies, oocytes were obtained by laparoscopic as opposed to by transvaginal ultrasound-guided techniques. Dense pelvic adhesions and ovarian disease may have significantly limited the ability to aspirate oocytes effectively in patients with more severe disease, thus compromising outcome. Using ultrasound-guided oocyte aspiration, Azem et al noted reduced fertilization, pregnancy, and birth rates per cycle in 58 patients with stages III and IV endometriosis in comparison with 60 controls with tubal factor infertility. Unfortunately, no comparisons were made with patients with less extensive disease, and, in addition, delivery rates were low in both of the groups (6.7% versus 16.6%, respectively). Pal and coworkers reported that although fertilization rates were significantly lower in patients with stage III and IV in comparison with stage I and II endometriosis, implantation, clinical pregnancy, and miscarriage rates were similar between the groups. Several large investigations have demonstrated no relationship between disease severity and ongoing pregnancy or miscarriage rates.

As part of the previously described meta-analysis, Barnhart et al also compared outcomes in patients previously diagnosed with stage I/II endometriosis to those with stage III/IV disease. Women with severe disease were noted to have significantly lower peak estradiol levels and number of oocytes retrieved as well as implantation and pregnancy rates than those with mild endometriosis.

More recently, Kuivasaari et al reported that despite a significantly younger mean age, implantation rates were lower for patients with stage III/IV endometriosis as opposed to either those with stage I/II disease or a control group with tubal infertility. Ballester and coworkers reported that patients with deeply infiltrative endometriosis, which would not typically be captured with standard scoring systems, have significantly lower pregnancy rates than endometriosis patients with more superficial lesions (58% versus 83%; p = 0.003). These investigators created a nomogram predicting pregnancy rates

### Table 1 Endometriosis and In Vitro Fertilization: 2010 SART Registry

<table>
<thead>
<tr>
<th>Age (y)</th>
<th>&lt; 35</th>
<th>35–37</th>
<th>38–40</th>
<th>41–42</th>
</tr>
</thead>
<tbody>
<tr>
<td>Live birth/cycle (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endometriosis</td>
<td>41.6</td>
<td>33.1</td>
<td>24.8</td>
<td>14.0</td>
</tr>
<tr>
<td>All diagnoses</td>
<td>41.7</td>
<td>31.9</td>
<td>22.1</td>
<td>12.5</td>
</tr>
<tr>
<td>Implantation rate (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endometriosis</td>
<td>36.7</td>
<td>26.4</td>
<td>18.0</td>
<td>11.3</td>
</tr>
<tr>
<td>All diagnoses</td>
<td>36.9</td>
<td>27.0</td>
<td>17.7</td>
<td>9.6</td>
</tr>
</tbody>
</table>

*Modified from 2010 Society for Assisted Reproductive Technology (SART) Clinic Summary Report.*
including such parameters as age, serum antimüllerian hormone (AMH) level, and number of cycles and reported that the presence of deeply infiltrative disease was the strongest predictor of clinical pregnancy.

**Are Outcomes Affected by the Presence of an Endometrioma?**

Although the presence of ovarian endometriotic cysts (endometriomas) should perhaps be addressed as an independent factor, it is difficult to truly assess the effect of these lesions on IVF outcome in isolation given that most of the patients with these lesions are likely to have concomitant peritoneal disease that could have an independent effect. The effect of endometrioma size per se has also not been evaluated as an independent variable.

Yanushpolsky et al reported a higher incidence of pregnancy loss, a decreased number of oocytes retrieved, as well as an adverse effect on embryo quality in endometrioma patients. In contrast, Olivennes et al demonstrated no impact of endometriomas on any outcome parameter. Several investigators described a decrease in ovarian response requiring the use of higher gonadotropin doses in patients with such lesions. However, cumulative pregnancy and live-birth rates were unaffected.

Somigliana and colleagues reported that this effect was more marked in those patients with multiple and/or larger cysts. In a more recent article, the same group compared the response of each ovary to gonadotropin stimulation in women with a unilateral endometrioma and noted that the development of follicles with a mean diameter >15 mm on the day of human chorionic gonadotropin administration was similar between the two sides. This finding was confirmed by others.

In a recent retrospective series, Ballester and coworkers reported that the total number of endometriomas, size of the largest lesions, and the presence of unilateral or bilateral lesions had no impact on cycle outcome. However, the presence of concomitant deeply infiltrating disease also had a significant and deleterious effect on the cumulative likelihood of pregnancy. Serum anti-AMH level also was highly predictive, which would emphasize the importance of completing a thorough evaluation of ovarian reserve (as well as the rest of a thorough infertility evaluation) before initiating therapy.

### Table 2

<table>
<thead>
<tr>
<th>Endometriosis stage</th>
<th>Tubal factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>I/II</td>
<td>III/IV</td>
</tr>
<tr>
<td>Patients</td>
<td>31</td>
</tr>
<tr>
<td>Cycles</td>
<td>58</td>
</tr>
<tr>
<td>Age, y</td>
<td>32.6 ± 4.4</td>
</tr>
<tr>
<td>Implantation rate (%)</td>
<td>28.3</td>
</tr>
</tbody>
</table>

*p < 0.05.*

*Modified from Kuivasari et al.*

**Does Surgical Management of Nonovarian Endometriosis Improve IVF Outcome?**

The effectiveness of surgical ablation or resection of endometriotic implants as the sole treatment of endometriosis-related subfertility has been addressed elsewhere. The question of whether such intervention in the absence of ovarian endometriomata would enhance IVF cycle outcome has been less extensively evaluated. One prospective randomized trial reported that, although laparoscopic carbon dioxide laser ablation of endometriosis at the time of gamete intralFallopian transfer (GIFT) had no effect on cycle outcome, pregnancy rates in subsequent cycles of patients who failed to conceive were significantly higher than in controls with endometriosis who underwent GIFT alone. A second trial evaluated two groups of patients with endometriosis who underwent surgery required significantly higher gonadotropin doses resulting in a lower number of oocytes retrieved, but implantation (32.1% versus 19 ± 25.1%; *p = 0.03*) and overall pregnancy rates (41% versus 24%,
p = 0.004) were significantly higher. The design of both of these studies is subject to selection bias. An additional weakness of the latter trial is the lack of definitive diagnosis of endometriosis in all patients. Thus one cannot draw definitive conclusions. In an analysis of patients with all stages of endometriosis who failed an initial IVF cycle and then underwent surgical resection prior to a second cycle, no differences in day 3 embryo quality were appreciated. The need for appropriately designed prospective randomized trials to address this issue are critical before one can state that surgical intervention prior to IVF is of benefit in any specific patient population.

**Does Pre-Cycle Resection of Endometriomas Affect IVF Outcomes?**

The question of whether resection of endometriomas either enhances or has a deleterious effect on IVF cycle outcome is addressed in detail elsewhere. However, two recent reviews of the literature are helpful. Tsoumpo et al published a meta-analysis of the effect of surgical treatment of endometriomas or expectant management on subsequent IVF cycles. Meta-analysis was performed on 5 of 20 eligible studies. These authors noted no significant differences in pregnancy rates or gonadotropin responses between the groups, suggesting little benefit in surgical intervention. In a more recent Cochrane Database review, Benschop and coworkers confirmed a lack of evidence of any benefit from either aspiration or cystectomy compared with expectant management with regard to clinical pregnancy rates or number of mature oocytes retrieved. Cystectomy was associated with a decreased response to controlled ovarian hyperstimulation in comparison with expectant management.

One of the presumed benefits of endometrioma resection was purported to be the avoidance of inadvertent exposure of oocytes to endometrioma fluid at the time of aspiration. However, at least one group of investigators has shown that such exposure has no impact on fertilization or early embryo development rates. Nevertheless, it does make sense to make every effort to avoid entering an endometrioma during oocyte retrieval procedures to prevent peritoneal leak of contents.

If resection of endometriomas prior to IVF is generally not beneficial, then can this intervention cause harm? Several investigators have shown that the response to gonadotropins of operated versus nonoperated ovaries was significantly reduced after unilateral cystectomy. Somigliana et al calculated that this corresponded to a 53% reduction in response (95% CI, 35 to 72) that was not affected by the size of the cyst excised. In fact, this same group reported that, of 93 women who underwent pre-cycle surgery for unilateral endometriomas, an absence of follicular growth in the operated but not the contralateral ovary occurred in 13% of cases. Others have failed to show such a deleterious effect, however.

Given the lack of convincing evidence supporting benefit of routine resection and potential surgical risk as well as damage to ovarian function, one would ask if there are any indications for removing an endometrioma prior to an IVF cycle. Garcia-Velasco and Somigliana recently published an elegant opinion article that addresses this issue. They claimed that it would be reasonable to consider surgical intervention in patients who have never previously undergone laparoscopy to confirm the diagnosis of endometriosis, those with progressive pain, those masses that exhibit rapid growth and/or have suspicious ultrasound features, those of a significant enough size to create concern for rupture in pregnancy, and an inability to access the remainder of the ovary. Others should be managed expectantly (►Table 3). However, when surgical intervention is undertaken, it is critical to use meticulous
techniques with a goal of carefully avoiding compromise of ovarian blood supply and destroying otherwise healthy normal tissue.

**Does Pre-IVF Cycle Medical Suppression Improve Outcomes?**

Traditional medical therapy for symptomatic endometriosis such as progestins, danazol, and gonadotropin-stimulating hormone (GnRH) agonists has been shown to have little impact on enhancing spontaneous pregnancy rates in infertile endometriosis patients. However, if the negative effect of this disease process on fertility returns rapidly after discontinuation of medication, then one could hypothesize that any benefits of medical suppression on enhancing fertility would be most evident if pregnancy could be achieved during a time of maximal suppression. This could only occur with the use of the assisted reproductive technologies.

Most of the investigations in this regard have examined prolonged use of GnRH agonists prior to IVF. In a prospective randomized multicenter trial, Surrey et al evaluated the effect of a 3-month course of a GnRH agonist administered immediately prior to initiating controlled ovarian hyperstimulation (COH) in preparation for IVF in 25 patients with surgically confirmed endometriosis. Significantly higher ongoing pregnancy rates with a trend toward higher implantation rates were appreciated in comparison to controls with endometriosis who underwent standard COH protocols and IVF without prolonged GnRH agonist therapy. Of note is the fact that a higher percentage of patients who received prolonged agonist therapy had more advanced disease, a group that one would expect to have inherently poorer outcomes.

These findings have been demonstrated by others. Seven previous studies of varying design have assessed the effect of suppression with a GnRH agonist (GnRHa) before IVF or GIFT. The length of suppression varied from 6 weeks to 7 months. Some studies lacked control groups, but a beneficial effect of pretreatment was suggested by all. Rickes and colleagues evaluated the effect of pre-cycle surgical treatment of endometriosis alone or in combination with a 6-month postoperative treatment course of a GnRHa on IVF or COH-intrauterine insemination (IUI) outcome in a prospective randomized trial of 110 patients. The pregnancy rates were significantly higher for both forms of fertility therapy in those patients treated with a prolonged postoperative GnRHa course. However, when patients were stratified based on disease stage, a statistically significant difference was only appreciated among patients with stages III/IV endometriosis who underwent IVF. A summary of the results of the randomized trials is displayed in Table 4.

Sallam et al more recently performed a Cochrane Database analysis of three of these prospective randomized trials including 163 endometriosis patients undergoing 3 to 6 months of pre-cycle GnRHa treatment. This intervention

---

**Table 3** Proposed Indications for Pre-In Vitro Fertilization Cycle Endometrioma Resection

- No prior surgical confirmation of endometriosis
- Severe pelvic pain attributable to mass
- Rapid growth
- Suspicious sonographic features
- Compromised access to remaining follicles
- Concern for rupture in pregnancy due to size

*Modified from Garcia-Velasco and Somigliana.*

---

**Figure 2** Ongoing pregnancy and implantation rates in endometriosis patients after a 3-month course of gonadotropin-releasing hormone agonist (GnRHa) versus control prior to in vitro fertilization. Modified from Surrey et al. (Fig. 1). *p < 0.05.
resulted in significantly improved rates of both live birth (OR: 9.1%; 95% CI, 1.08 to 78.22) and clinical pregnancy (OR: 4.28; 95% CI, 2.0 to 9.15).

There are no studies that compare varying lengths of suppressive therapy or whether this approach should be offered to specific subgroups of endometriosis patients given the associated increased expense and time delay before pregnancy can occur.

The mechanism of action of this effect has not been clearly established. It has been suggested that, aside from their primary mechanism, GnRHa may act to diminish concentrations of peritoneal fluid metalloproteinase tissue inhibitors, downregulate peritoneal fluid inflammatory proteins, and increase apoptosis and expression of pro-apoptotic proteins. Others have shown that GnRHa may significantly decrease endometrial nitric oxide synthase expression.

A great deal of interest has surrounded the role of endometrial β3 integrin expression in this setting. Lessey et al previously demonstrated that administration of a GnRHa for 3 months to women with stage I/II endometriosis and aberrant endometrial β3 integrin expression resulted in a 64% rate of return of expression. Ruan and coworkers reported that, in a murine model, impaired endometrial β3 integrin and leukemia-inhibitory factor expression as well as uterine receptivity resulting from ovarian stimulation were partially restored after GnRHa administration.

Given that the pregnancy rate in control patients who were not administered prolonged agonist therapy still remained relatively high in the trial by Surrey et al, it is clear that not all endometriosis patients require this intervention. These data beg the question of whether endometrial β3 integrin expression can be used as a marker to determine which patients might be candidates for prolonged pre-cycle GnRHa therapy. In a case-control study of 74 consecutive IVF candidates believed to be at high risk for implantation defects due to prior IVF failure despite adequate embryo quality and/or endometriosis, we reported a 48.6% prevalence of absent endometrial integrin expression. Of those who had undergone laparoscopy, 52.8% had a diagnosis of endometriosis of whom 57.1% had stage III/IV disease. Miller and coworkers reported that live-birth rates from IVF were significantly increased in patients with positive versus negative integrin expression (38% versus 7%; p < 0.05). Farrell and colleagues reported a small series of 11 patients with aberrant integrin expression and in phase endometrial biopsies who were administered an 8-week course of a GnRH agonist in conjunction with norethisterone acetate prior to IVF. Nine experienced ongoing pregnancies.

In an effort to resolve this issue, Surrey and colleagues recently reported the results of a prospective randomized pilot trial of 36 endometriosis patients undergo IVF. The patients were randomized after assessing β3 integrin expression to receive either 3 months of GnRHa prior to initiating ovarian stimulation or to proceed directly to ovarian stimulation. Interestingly, a trend toward higher pregnancy rates that did not achieve statistical significance was noted in integrin-positive patients administered prolonged GnRHa. This is the opposite of what one would have predicted. In this study, the value of a negative biopsy in predicting ongoing IVF pregnancy after integrin expression was only 44.4% (Fig. 3). These results would either suggest that evaluating integrin expression is of little value in determining which patients would benefit from prolonged GnRHa, or they may have been confounded by a limited sample size or by the fact that patients in the control groups moved directly to IVF after biopsy, whereas study group patients did not undergo stimulation for 3 months. There are data suggesting that the performance of an endometrial biopsy alone may enhance implantation rates as a result of the localized injury, particularly in patients with a history of implantation failure.

There are a host of other unresolved issues. We do not know the ideal duration of therapy. Is there a need for

---

**Table 4** In Vitro Fertilization and Endometriosis: Prolonged Pre-Cycle Gonadotropin-Releasing Hormone Agonist

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Patients/Cycles</th>
<th>Clinical Pregnancy Rates (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No GnRHa</td>
<td>Standard GnRHa</td>
<td>Prolonged GnRHa (duration)</td>
</tr>
<tr>
<td>Chedid et al44</td>
<td>Retrospective</td>
<td>145/174</td>
<td>23*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Standard GnRHa</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>39</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>46</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(3 mo)</td>
</tr>
<tr>
<td>Nakamura et al30</td>
<td>Retrospective</td>
<td>32/32</td>
<td>27*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Standard GnRHa</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>67</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(126 ± 57) d</td>
</tr>
<tr>
<td>Marcus and Edwards49</td>
<td>&quot;Semi-randomized&quot;</td>
<td>84/181</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Standard GnRHa</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>35</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(2-7 mo)</td>
</tr>
<tr>
<td>Remorgida et al46</td>
<td>Prospective randomized</td>
<td>60</td>
<td>33</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Standard GnRHa</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>32</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>56</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(6 mo)</td>
</tr>
<tr>
<td>Dicker et al48</td>
<td>Prospective randomized</td>
<td>64</td>
<td>5*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Standard GnRHa</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>33</td>
</tr>
<tr>
<td>Surrey et al43</td>
<td>Prospective randomized</td>
<td>51/51</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Standard GnRHa</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>56.5*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>78.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(3 mo)</td>
</tr>
<tr>
<td>Rickes et al51</td>
<td>Postoperative prospective randomized</td>
<td>47/82</td>
<td>47</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Standard GnRHa</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>75</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(6 mo)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Stage I/II</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>50</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>56</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Stage III/IV</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>40*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>82</td>
</tr>
</tbody>
</table>

GnRHa, gonadotropin-releasing hormone agonist.

*p < 0.05 versus prolonged GnRHa.
repeated courses of therapy if an initial cycle is unsuccessful? A significant concern with the administration of GnRHa to patients with compromised or diminished ovarian reserve is the deleterious effect on ovarian response to subsequent gonadotropin therapy. In this circumstance, it may be wise to vitrify all embryos after appropriate stimulation and then administer the GnRHa prior to endometrial preparation for frozen embryo transfer.

There is even more limited data regarding the use of other suppressive medical therapies. Tei et al reported nine patients with reduced endometrial integrin expression. Repeated IVF failures who were treated with a 12-week course of danazol 400 mg showed a significant increase in expression in the first ovulatory cycle after completion of therapy. No clinical outcomes were reported, however.

More recently, Miller and colleagues reported that the administration of the aromatase inhibitor letrozole 5 mg daily for days 2 to 6 of gonadotropin stimulation resulted in cycle outcomes that were similar to patients who were integrin receptor positive and not treated with this agent. The weakness of this retrospective trial is the fact that the authors did not randomize integrin-negative patients to similar protocols with or without the use of letrozole. Although the results are encouraging, it is difficult to draw definitive conclusions.

De Ziegler and coinvestigators recently evaluated the role of a 6- to 8-week course of oral contraceptives in patients planning IVF with either surgically diagnosed endometriosis or those with sonographic suspicion of the presence of endometriosis. The use of oral contraceptives resulted in higher pregnancy rates per retrieval than in controls (35% versus 12.9%, p = 0.01). This impact was even greater in those with presumed endometriomas. It is important to note that this was a retrospective trial and that control patients were both significantly older and had higher baseline follicle-stimulating hormone levels. An additional concern is the lack of documentation of endometriosis in all patients.

The dearth of appropriately designed randomized trials makes it difficult to determine which subset of endometriosis patients would benefit from pre-IVF cycle GnRHa (or potentially other suppressive therapy). I would propose that suppressive intervention be considered in the subsets of infertile endometriosis patients with significantly advanced disease, those with severe pain, and/or those with a history of prior IVF cycle failure particularly after transfer of good quality embryos.

**Does IVF Have an Impact on Endometriosis?**

Most of this article has been devoted to a discussion of whether endometriosis and its treatments have an impact on IVF outcome. It is perhaps appropriate to also ask whether IVF and COH have an impact on the progression of endometriosis given the resulting supraphysiologic estradiol levels that could theoretically stimulate disease progression. There is a limited amount of data in this regard, but the results are reassuring.

D’Hooghe et al evaluated 67 patients with stage III/IV endometriosis who underwent ovarian stimulation after surgery for either IVF and/or IUI. Cumulative disease recurrence as calculated by life table analysis was lower after stimulation for IVF than for IUI cycles despite exposure to significantly higher circulating estradiol levels. Similarly, Benaglia and colleagues noted no worsening in endometriosis symptom scores or change in size of either endometriomas or peritoneal nodules evaluated by serial transvaginal ultrasound examinations in the 3 to 6 months after an IVF cycle. The authors reported that 22% reported improvement in
symptoms, whereas 11% reported worsening of symptoms during this follow-up period.

Conclusions

Although IVF clearly represents the most efficient way for infertile endometriosis patients to conceive, less invasive alternatives should not be ignored. Taken as a whole, patients with endometriosis should expect similar age-based outcomes from IVF as other patients. The possible exception to this contention may be the individual with advanced ovarian disease who may require more aggressive stimulation resulting in a more compromised number of oocytes and embryos.

There is inconclusive evidence to suggest that pre-cycle surgical ablation of superficial endometriosis is of benefit in enhancing IVF outcome, although the outcomes are more encouraging from a small number of studies with weaknesses in design specifically addressing the effects of resecting deeply infiltrative disease. The impact of endometriomas on IVF outcome is not overcome by resection. The indications for doing so should be limited to patients without prior diagnosis of endometriosis, those with symptoms directly related to the mass, rapidly growing lesions particularly with suspicious features, and masses that significantly limit safe access to normal ovarian tissue for oocyte aspiration. Care must be taken to preserve ovarian blood supply and normal ovarian tissue if endometrioma resection is considered to minimize any iatrogenic impact on ovarian reserve.

The administration of a prolonged course of GnRHa, and possibly other suppressive agents, appears to improve IVF cycle outcome. However, the ideal subset of endometriosis patients who are candidates for this approach has not been adequately defined. Nevertheless, primary attention might be given to those with more severe disease with severe pain and/ or a history of implantation failure.

It goes without saying that patients with endometriosis who are IVF candidates should undergo the same thorough pre-cycle evaluation as any other patient. This should include at minimum an assessment of ovarian reserve, tubal patency, the uterine cavity, and sperm function. In this way, appropriate pre-cycle therapy, ovarian stimulation protocols, and laboratory techniques can be planned to maximize a successful outcome.

References

1 Society for Assisted Reproductive Technology. 2010 Clinic summary report. Available at: www.sartcorsonline.com
41 Garcia-Velasco JA, Somigliana E. Management of endometriomas in women requiring IVF: to touch or not to touch. Hum Reprod 2009;24(3):496–501
53 Sharpe-Timms KL, Keisler LW, McIntosh EW, Keisler DH. Tissue inhibitor of metalloproteinase-1 concentrations are attenuated in peritoneal fluid and sera of women with endometriosis and restored in sera by gonadotropin-releasing hormone agonist therapy. Fertil Steril 1998;69(6):1128–1134


